Bioapplications of poly(amidoamine) (PAMAM) dendrimers in nanomedicine
Source abstract
Abstract
Poly(amidoamine) (PAMAM) dendrimers are a novel class of spherical, well-designed branching polymers with interior cavities and abundant terminal groups on the surface which can form stable complexes with drugs, plasmid DNA, oligonucleotides, and antibodies. Amine‐terminated PAMAM dendrimers are able to solubilize different families of hydrophobic drugs, but the cationic charges on dendrimer surface may disturb the cell membrane. Therefore, surface modification by PEGylation, acetylation, glycosylation, and amino acid functionalization is a convenient strategy to neutralize the peripheral amine groups and improve dendrimer biocompatibility. Anticancer agents can be either encapsulated in or conjugated to dendrimer and be delivered to the tumor via enhanced permeability and retention (EPR) effect of the nanoparticle and/or with the help of a targeting moiety such as antibody, peptides, vitamins, and hormones. Biodegradability, non-toxicity, non-immunogenicity, and multifunctionality of PAMAM dendrimer are the key factors which facilitate steady increase of its application in drug delivery, gene transfection, tumor therapy, and diagnostics applications with precision and selectivity. This review deals with the major topics of PAMAM dendrimers including structure, synthesis, toxicity, surface modification, and also possible new applications of these spherical polymers in biomedical fields as dendrimer-based nanomedicine.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Chemical Synthesis and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Albertazzi L, Gherardini L, Brondi M, Sato SS, Bifone A (2013) In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry. Mol Pharm 10:249–260. doi: 10.1021/mp300391v10.1021/mp300391v ↗
2. Asthana A, Chauhan AS, Diwan PV, Jain NK (2005) Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSciTech 6:536–542. doi: 10.1208/pt06036710.1208/pt060367 ↗
3. Astruc D, Liang L, Rapakousiou A, Ruiz J (2012) Click dendrimers and triazole-related aspects: catalysts, mechanism, synthesis, and functions a bridge between dendritic architectures and nanomaterials. Acc Chem Res 45:630–640. doi: 10.1021/ar200235m10.1021/ar200235m ↗
4. Aulenta F, Hayes W, Rannard S (2003) Dendrimers: a new class of nanoscopic containers and delivery devices. Eur Polym J 39:1741–1771. doi: 10.1016/S0014-3057(03)00100-910.1016/S0014-3057(03)00100-9 ↗
5. Bai CZ, Choi S, Nam K, An S, Park JS (2013) Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. Int J Pharm 445:79–87. doi: 10.1016/j.ijpharm.2013.01.05710.1016/j.ijpharm.2013.01.057 ↗
6. Balaji BS, Lewis MR (2009) Double exponential growth of aliphatic polyamide dendrimers via AB2 hypermonomer strategy. Chem Commun 4593–4595. doi: 10.1039/B903948A10.1039/b903948a ↗
7. Baos U, Christensen JB, Heegaard PMH (2006) Dendrimers: design, synthesis and chemical properties. J Mater Chem 16:3785–3798. doi:101039/B611813P10.1039/b611813p ↗
8. Barrett T, Ravizzini G, Choyke PL, Kobayashi H (2009) Dendrimers application related to bioimaging. IEEE Eng Med Biol Mag 28:12–22. doi: 10.1109/MEMB.2008.93101210.1109/MEMB.2008.931012 ↗
9. Barth RF, Adams DM, Soloway AH, Alam F, Darbyt MV (1994) Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug Chem 5:58–66. doi: 10.1021/bc00025a00810.1021/bc00025a008 ↗
10. Beezer AE, King AS, Martin IK, Mitchel JC, Twyman LJ, Wain CF (2003) Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives. Tetrahedron 59:3873–3880. doi: 10.1016/S0040-4020(03)00437-X10.1016/S0040-4020(03)00437-X ↗
11. Bhadra D, Bhadra S, Jain S, Jain NK (2003) PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 257:111–124. doi: 10.1016/S0378-5173(03)00132-710.1016/S0378-5173(03)00132-7 ↗
12. Bielawski K, Bielawska A, Muszyn AM, Poplawska B (2011) Cytotoxic activity of G3 PAMAM-NH2 dendrimer-chlorambucil conjugate in human breast cancer cells. Environ Toxicol Pharmacol 3:364–372. doi: 10.1016/j.etap.2011.08.00210.1016/j.etap.2011.08.002 ↗
13. Bielinska AU, Kukowska-Latallo JF, Baker JR (1997) The interaction of plasmid DNA with polyamidoamine dendrimers: mechanism of complex formation and analysis of alterations induced in nuclease sensitivity and transcriptional activity of the complexed DNA. Biochim Biophys Acta 1353:180–190. doi: 10.1016/S0167-4781(97)00069-910.1016/S0167-4781(97)00069-9 ↗
14. Bielinska AU, Chen C, Johnson J, Baker JR (1999) DNA complexing with polyamidoamine dendrimers: implications for transfection. Bioconjug Chem 10:843–850. doi: 10.1021/bc990036k10.1021/bc990036k ↗
15. Borowska K, Laskowska B, Magon A, Mysliwiec B, Pyda M, Wolowiec S (2010) PAMAM dendrimers as solubilizers and hosts for 8-methoxypsoralene enabling transdermal diffusion of the guest. Int J Pharm 398:185–189. doi: 10.1016/j.ijpharm.2010.07.01910.1016/j.ijpharm.2010.07.019 ↗
16. Borowska K, Wolowiec S, Rubaj A, Glowniak K, Sieniawska E, Radej S (2012) Effect of polyamidoamine dendrimer G3 and G4 on skin permeation of 8-methoxypsoralene—in vivo study. Int J Pharm 426:280–283. doi: 10.1016/j.ijpharm.2012.01.04110.1016/j.ijpharm.2012.01.041 ↗
17. Bosman AW, Janssen HM, Meijer EW (1999) About dendrimers: structure, physical properties, and applications. Chem Rev 99:1665–1688. doi: 10.1021/cr970069y10.1021/cr970069y ↗
18. Braun CS, Vetro JA, Tomalia DA, Koe GS, Koe JG, Middaugh CR (2005) Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles. J Pharm Sci 94:423–436. doi: 10.1002/jps.2025110.1002/jps.20251 ↗
19. Brothers HM, Piehler LT, Tomalia DA (1998) Slab-gel and capillary electrophoretic characterization of polyamidoamine dendrimers. J Chromatogr A 814:233–246. doi: 10.1016/S0021-9673(98)00419-110.1016/S0021-9673(98)00419-1 ↗
20. Buczkowski A, Sekowski S, Grala A, Palecz D, Milowski K (2011) Interaction between PAMAM-NH2 G4 dendrimer and 5-fluorouracil in aqueous solution. Int J Pharm 408:266–270. doi: 10.1016/j.ijpharm.2011.02.01410.1016/j.ijpharm.2011.02.014 ↗
21. Buczkowski A, Urbaniak P, Palcez B (2012) Thermochemical and spectroscopic studies on the supramolecular complex of PAMAM-NH2 G4 dendrimer and 5-fluorouracil in aqueous solution. Int J Pharm 428:178–182. doi: 10.1016/j.ijpharm.2012.03.00410.1016/j.ijpharm.2012.03.004 ↗
22. Bullen HA, Hemmer R, Haskamp A, Cason C, Wall S, Spaulding R, Rossow B, Hester M, Caroway M, Haik KL (2011) Evaluation of biotinylated PAMAM dendrimer toxicity in models of the blood brain barrier: a biophysical and cellular approach. J Biomater Nanobiotechnol 2:485–493. doi: 10.4236/jbnb.2011.22505910.4236/jbnb.2011.225059 ↗
23. Campagna S, Ceroni P, Puntoriero F (2012) Designing dendrimers. John Wiley and Sons, Hoboken
24. Cason CA, Fabre TA, Buhrlage A, Hail KL, Bullen HA (2012) Low-level detection of poly(amidoamine) PAMAM dendrimers using immunoimaging scanning probe microscopy. Int J Anal Chem 1–8. doi: 10.1155/2012/34126010.1155/2012/341260 ↗
25. Cevc G, Vierl U (2010) Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release 141:277–299. doi: 10.1016/j.jconrel.2009.10.01610.1016/j.jconrel.2009.10.016 ↗
26. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV (2007a) Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. J Biomed Mater Res A 82:92–103. doi: 10.1002/jbm.a.3112210.1002/jbm.a.31122 ↗
27. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV (2007b) The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 28:504–512. doi: 10.1016/j.biomaterials.2006.07.04610.1016/j.biomaterials.2006.07.046 ↗
28. Charles S, Vasanthan N, Kwon D, Sekosan G, Ghosh S (2012) Surface modification of poly(amidoamine) (PAMAM) dendrimer as antimicrobial agents. Tetrahedron Lett 53:6670–6675. doi: 10.1016/j.tetlet.2012.09.09810.1016/j.tetlet.2012.09.098 ↗
29. Chauhan AS, Jain NK, Diwan PV, Khopade AJ (2004) Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J Drug Target 12:575–583. doi: 10.1080/1061186040001065510.1080/10611860400010655 ↗
30. Chen W, Tomalia DA, Thomas JL (2000) Unusual pH-dependent polarity changes in PAMAM dendrimers: evidence for pH-responsive conformational changes. Macromolecules 33:9169–9172. doi: 10.1021/ma000791p10.1021/ma000791p ↗
31. Chen Y, Wang G, Kong D, Zhang Z, Yang K, Liu R, Zhao W, Xu Y (2013) Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer. Mol Carcinog 52:237–246. doi: 10.1002/mc.2185010.1002/mc.21850 ↗
32. Cheng Y (2012) Dendrimer-based drug delivery systems: from theory to practice. John Wiley and sons, Hoboken10.1002/9781118275238 ↗
33. Cheng Y, Xu T (2005a) Dendrimers as potential drug carriers part I solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem 40:1188–1192. doi: 10.1016/j.ejmech.2005.06.01010.1016/j.ejmech.2005.03.009 ↗
34. Cheng Y, Xu T (2005b) Solubility of nicotinic acid in polyamidoamine dendrimer solutions. Eur J Med Chem 40:1384–1389. doi: 10.1016/j.ejmech.2005.08.00110.1016/j.ejmech.2005.03.009 ↗
35. Cheng Y, Xu T, Rongqiang F (2005) Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur J Med Chem 40:1390–1393. doi: 10.1016/j.ejmech.2005.08.00210.1016/j.ejmech.2005.03.009 ↗
36. Cheng Y, Xu Z, Ma M, Xu T (2008) Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci 97:123–143. doi: 10.1002/jps.2107910.1002/jps.21079 ↗
37. Cheng Y, Zhao L, Li Y, Xu T (2011) Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem Soc Rev 40:2673–2703. doi: 10.1039/C0CS00097C10.1039/c0cs00097c ↗
38. Choi JS, Nam K, Park JY, Kim JB, Lee JK, Park JS (2004) Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-argenine. J Control Release 99:445–456. doi: 10.1016/j.jconrel.2004.07.02710.1016/j.jconrel.2004.07.027 ↗
39. Choi Y, Thomas T, Kotlyar A, Islam MT, Baker JR (2005) Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chem Biol 12:35–43. doi: 10.1016/j.chembiol.2004.10.01610.1016/j.chembiol.2004.10.016 ↗
40. Ciolkowski M, Petersen JF, Ficker M, Janaszewska A, Christensen JB, Klajnert B, Bryszewska M (2012) Surface modification of PAMAM dendrimer improves its biocompability. Nanomed Nanotechnol Biol Med 8:815–817. doi: 10.1016/j.nano.2012.03.00910.1016/j.nano.2012.03.009 ↗
41. Cloninger MJ (2002) Biological applications of dendrimers. Curr Opin Chem Biol 6:742–748. doi: 10.1016/S1367-5931(02)00400-310.1016/S1367-5931(02)00400-3 ↗
42. Crampton HL, Simanek EE (2007) Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. Polym Int 2(56):489–496. doi: 10.1002/pi.223010.1002/pi.2230 ↗
43. D’ Emanuele A, Jevprasesphant R, Penny J, Attwood D (2004) The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 95:447–453. doi: 10.1016/j.jconrel.2003.12.00610.1016/j.jconrel.2003.12.006 ↗
44. D’Emanuele A, Attwood D (2005) Dendrimer–drug interactions. Adv Drug Deliv Rev 57:2147–2162. doi: 10.1016/j.addr.2005.09.01210.1016/j.addr.2005.09.012 ↗
45. Delong R, Stephenson K, Loftus T, Fisher M, Alahari S, Nolting A, Juliano ARL (1997) Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci 86:762–764. doi: 10.1021/js960409f10.1021/js960409f ↗
46. Devarakonda B, Villiers MM (2005) Effect of polyamidoamine (PAMAM) dendrimers on the in vitro release of water-insoluble nifedipine from aqueous gels. AAPS PharmSciTech 6:504–512. doi: 10.1208/pt06036310.1208/pt060363 ↗
47. Devarakonda B, Hill RA, De Villiers MM (2004) The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. Int J Pharm 284:133–140. doi: 10.1016/j.ijpharm.2004.07.00610.1016/j.ijpharm.2004.07.006 ↗
48. Devarakonda B, Hill RA, Liebenberg W, Brits M, Villiers MM (2005) Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm 304:193–209. doi: 10.1016/j.ijpharm.2005.07.02310.1016/j.ijpharm.2005.07.023 ↗
49. Devarakonda B, Otto DP, Judefeind A, Hill RA, Villiers MM (2007) Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int J Pharm 345:142–153. doi: 10.1016/j.ijpharm.2007.05.03910.1016/j.ijpharm.2007.05.039 ↗
50. Dobrovolskaia MA, Patri AK, Simak J, Hall JB, Semberova J, Lacerda SHP, McNeil SE (2012) Nanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm 9:382–393. doi: 10.1021/mp200463e10.1021/mp200463e ↗
51. Doshi M (2011) Dendrimer and its application. Int J Pharm Sci Rev Res 7:104–111
52. Duan S, Kouketsu T, Kazama S, Yamada K (2006) Development of PAMAM dendrimer composite membranes for CO2 separation. J Membr Sci 283:2–6. doi: 10.1016/j.memsci.2006.06.02610.1016/j.memsci.2006.06.026 ↗
53. Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57:2215–2237. doi: 10.1016/j.addr.2005.09.01910.1016/j.addr.2005.09.019 ↗
54. Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR (2000) The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. PSTT 3:232–245. doi: 10.1016/S1461-5347(00)00273-X
55. Esfand R, Tomalia DA (2001) Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. DDT 6:427–436. doi: 10.1016/S1359-6446(01)01757-310.1016/S1359-6446(01)01757-3 ↗
56. Filipowicz A, Wolowiec S (2011) Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM dendrimers. Int J Pharm 408:152–156. doi: 10.1016/j.ijpharm.2011.01.03310.1016/j.ijpharm.2011.01.033 ↗
57. Filipowicz A, Wolowiec S (2012) Bioconjugates of PAMAM dendrimers with trans-retinal, pyridoxal, and pyridoxal phosphate. Int J Nanomed 7:4819–4828. doi: 10.2147/IJN.S34175
58. Gautam SP, Verma A (2012) PAMAM dendrimers: novel polymeric nanoarchitectures for solubility enhancement of candesartan cilexetil, research gate. Pharm Sci 1:1–4
59. Gillies ER, Frechet JMJ (2005) Dendrimers and dendritic polymers in drug delivery. DDT 10:35–43. doi: 10.1016/S1359-6446(04)03276-310.1016/S1359-6446(04)03276-3 ↗
60. Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM (2006) Activity of dendrimer–methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem 17:275–283. doi: 10.1021/bc050185510.1021/bc0501855 ↗
61. Haba Y, Kojima C, Harada A, Ura T, Horinaka H, Kono K (2007) Preparation of poly(ethylene glycol)-modified poly(amido amine) dendrimers encapsulating gold nanoparticles and their heat-generating ability. Langmuir 23:5243–5246. doi: 10.1021/la070082610.1021/la0700826 ↗
62. Haensler J, Szoka FC (1993) Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 4:372–379. doi: 10.1021/bc00023a01210.1021/bc00023a012 ↗
63. Han SC, Kim JH, Lee JW (2012) Convergent synthesis of PAMAM dendrimers containing tetra(ethyleneoxide) at core using click chemistry. Bull Korean Chem Soc 33:3501–3504. doi: 10.5012/bkcs.2012.33.10.350110.5012/bkcs.2012.33.10.3501 ↗
64. Hawker CJ, Frkchet JMJ (1990) Preparation of polymers with controlled molecular architecture a new convergent approach to dendritic macromolecules. J Am Chem Soc 112:7638–7647. doi: 10.1021/ja00177a02710.1021/ja00177a027 ↗
65. Hong S, Bielinska AU, Mecke A, Keszler B, Beals JL, Shi X, Balogh L, Orr BG, Baker JR, Holl MMB (2004) Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem 15:774–782. doi: 10.1021/bc049962b10.1021/bc049962b ↗
66. Horiguchi Y, Kudo S, Nagasaki Y (2011) Gd@C82 metallofullerenes for neutron capture therapy—fullerene solubilization by poly(ethylene glycol)-block-poly(2-(N, N-diethylamino)ethyl methacrylate) and resultant efficacy in vitro. Sci Technol Adv Mater 12:1–7. doi: 10.1021/cr300297r10.1088/1468-6996/12/4/044607 ↗
67. Hu J, Cheng Y, Wu Q, Zhao L, Xu T (2009) Host-guest chemistry of dendrimer-drug complexes 2 effects of molecular properties of guests and surface functionalities of dendrimers. J Phys Chem B 113:10650–10659. doi: 10.1021/jp904705510.1021/jp9047055 ↗
68. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C (2007) Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 21:1117–1125. doi: 10.1096/fj.06-7380com10.1096/fj.06-7380com ↗
69. Ina M (2011) Dendrimer: a novel drug delivery system. J Drug Deliv Therap 1:70–74
70. Inoue K (2000) Functional dendrimers, hyperbranched and star polymers. Prog Polym Sci 25:453–571. doi: 10.1016/S0079-6700(00)00011-310.1016/S0079-6700(00)00011-3 ↗
71. Jain K, Kesharwani P, Gupta U, Jain NK (2010) Dendrimer toxicity: let’s meet the challenge. Int J Pharm 394:122–142. doi: 10.1016/j.ijpharm.2010.04.02710.1016/j.ijpharm.2010.04.027 ↗
72. Jana S, Gandhi A, Sen KK, Basu SK (2012) Dendrimers: synthesis, properties, biomedical and drug delivery applications. Am J Pharm Tech Res 2:32–55
73. Janaszewska A, Ciolkowski M, Wrobel D, Petersen JF, Ficker M, Christensen JB, Bryszewska M, Klajnert B (2013) Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups reveals negligible toxicity against three rodent cell-lines. Nanomed Nanotechnol Biol Med 9:461–464. doi: 10.1016/j.nano.2013.01.01010.1016/j.nano.2013.01.010 ↗
74. Jang WD, Nakagishi Y, Nishiyama N, Kawauchi S, Morimoto Y, Kikuchi M, Kataoka K (2006) Polyion complex micelles for photodynamic therapy: incorporation of dendritic photosensitizer excitable at long wavelength relevant to improved tissue-penetrating property. J Control Release 113:73–79. doi: 10.1016/j.jconrel.2006.03.00910.1016/j.jconrel.2006.03.009 ↗
75. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D’Emanuele A (2003) The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 252:263–266. doi: 10.1016/S0378-5173(02)00623-310.1016/S0378-5173(02)00623-3 ↗
76. Jia L, Xu JP, Wang H, Ji J (2011) Polyamidoamine dendrimers surface-engineered with biomimetic phosphorylcholine as potential drug delivery carriers. Colloids Surf B 84:49–54. doi: 10.1016/j.colsurfb.2010.12.01210.1016/j.colsurfb.2010.12.012 ↗
77. Jin GW, Koo H, Nam K, Kim H, Lee S, Park JS, Lee Y (2011) PAMAM dendrimer with a 1,2-diaminoethane surface facilitates endosomal escape for enhanced pDNA delivery. Polymer 52:339–346. doi: 10.1016/j.polymer.2010.10.06610.1016/j.polymer.2010.10.066 ↗
78. Joo WJ, Choi TL, Lee SK, Chung Y, Jung MS, Kim JM (2006) Electronically controlled nonvolatile memory device using PAMAM dendrimer. Org Electron 7:600–606. doi: 10.1016/j.orgel.2006.10.00110.1016/j.orgel.2006.10.001 ↗
79. Khandare J, Kolhe P, Pillai O, Kannan S, Lieh-Lai M, Kanna RM (2005) Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconjug Chem 16:330–337. doi: 10.1021/bc049801810.1021/bc0498018 ↗
80. Kim Y, Zimmerman SC (1998) Applications of dendrimers in bio-organic chemistry. Curr Opin Chem Biol 2:733–742. doi: 10.1016/S1367-5931(98)80111-710.1016/S1367-5931(98)80111-7 ↗
81. Kitchens KM, Kolhatkar RB, Swaan P, Ghandehari H (2008) Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol Pharm 5:364–369. doi: 10.1021/mp700089s10.1021/mp700089s ↗
82. Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Brechbiel MW, Star RA (2003) Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem 14:388–394. doi: 10.1021/bc025633c10.1021/bc025633c ↗
83. Kobayashi H, Kawamoto S, Bernardo M, Brechbiel MW, Knopp MV, Choyke PL (2006) Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J Control Release 111:343–351. doi: 10.1016/j.jconrel.2005.12.01910.1016/j.jconrel.2005.12.019 ↗
84. Koc FE, Senel M (2013) Solubility enhancement of non-steroidal anti-inflammatory drugs (NSAIDs) using polypolypropylene oxide core PAMAM dendrimers. Int J Pharm 451:18–22. doi: 10.1016/j.ijpharm.2013.04.06210.1016/j.ijpharm.2013.04.062 ↗
85. Kofoed J, Reymond JL (2005) Dendrimers as artificial enzymes. Curr Opin Chem Biol 9:656–664. doi: 10.1016/j.cbpa.2005.10.01310.1016/j.cbpa.2005.10.013 ↗
86. Kojima C, Kono K, Maruyama K, Takagishi T (2000) Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem 11:910–917. doi: 10.1021/bc000058310.1021/bc0000583 ↗
87. Kojima C, Toi Y, Harada A, Kono K (2007) Preparation of poly(ethylene glycol)-attached dendrimers encapsulating photosensitizers for application to photodynamic therapy. Bioconjug Chem 18:663–670. doi: 10.1021/bc060244u10.1021/bc060244u ↗
88. Kojima C, Turkbey B, Ogawa M, Bernardo M, Regino CAS, Bryant H, Choyke PL, Kono K, Kobayashi H (2011) Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomed Nanotechnol Biol Med 7:1001–1008. doi: 10.1016/j.nano.2011.03.00710.1016/j.nano.2011.03.007 ↗
89. Kolhatkar RB, Kitchens KM, Swaan PW, Ghandehari H (2007) Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem 18:2054–2060. doi: 10.1021/bc060388910.1021/bc0603889 ↗
90. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M (2003) Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm 259:143–160. doi: 10.1016/S0378-5173(03)00225-410.1016/S0378-5173(03)00225-4 ↗
91. Kolhe P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, Kannan RM (2006) Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. Biomaterials 27:660–669. doi: 10.1016/j.biomaterials.2005.06.00710.1016/j.biomaterials.2005.06.007 ↗
92. Kono K, Fukui T, Takagishi T, Sakurai S, Kojima C (2008a) Preparation of poly(ethylene glycol)-modified poly(amidoamine) dendrimers with a shell of hydrophobic amino acid residues and their function as a nanocontainer. Polymer 49:2832–2838. doi: 10.1016/j.polymer.2008.04.04810.1016/j.polymer.2008.04.048 ↗
93. Kono K, Kojima C, Hayashi N, Nishisaka E, Kiura K, Watarai S, Harada A (2008b) Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. Biomaterials 29:1664–1675. doi: 10.1016/j.biomaterials.2007.12.01710.1016/j.biomaterials.2007.12.017 ↗
94. Kukowska-Latallo JF, Bielinska AU, Johnson J, Spindler R, Tomalia DA, Baker JR (1996) Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 93:4897–4902. doi: 10.2307/3887310.1073/pnas.93.10.4897 ↗
95. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65:5317–5324. doi: 10.1158/0008-5472.CAN-04-392110.1158/0008-5472.CAN-04-3921 ↗
96. Kumar A, Yellepeddi VK, Davies GE, Strychar KB, Palakurthi S (2010a) Enhanced gene transfection efficiency by polyamidoamine (PAMAM) dendrimers modified with ornithine residues. Int J Pharm 392:294–303. doi: 10.1016/j.ijpharm.2010.03.05410.1016/j.ijpharm.2010.03.054 ↗
97. Kumar P, Meena KP, Kumar P, Choudhary C, Thakur DS, Bajpayee P (2010b) Dendrimer: a novel polymer for drug delivery. JITPS 1:252–269
98. Kumar PD, Kumar PV, Selvam TP, Rao S (2013a) Prolonged drug delivery system of PEGylated PAMAM dendrimers with a anti-HIV drug. Res Pharm 3:8–17
99. Kumar PD, Kumar PV, Selvam TS, Rao S (2013b) PEG conjugated PAMAM dendrimers with a anti-HIV drug stavudine for prolong release. Res Biotechnol 4:10–18
100. Kurtoglu YE, Mishra MK, Kannan S, Kannan RM (2010) Drug release characteristics of PAMAM dendrimer–drug conjugates with different linkers. Int J Pharm 384:189–194. doi: 10.1016/j.ijpharm.2009.10.01710.1016/j.ijpharm.2009.10.017 ↗